Ali Nebioğlu

Dr. Ali Nebioğlu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in International Journal Of Impotence Research
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
MBMert Başaranoğlu
Mert Başaranoğlu
SÇSelahittin Çayan
Selahittin Çayan
Erectile complaints are prevalent among young adults, with various factors potentially affecting sexual function and quality of life. This study investigates the impact of sleep quality and chronotype on erectile function in young adults who present with self-reported erectile difficulties. In this prospective study, 249 men with ED were included, assessed from January 2023 to July 2024. Sociodemographic and clinical data were collected for all participants, including age, body mass index (BMI), comorbid diseases, and hormonal parameters. All patients completed the following questionnaires: International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI), Morningness-Eveningness Questionnaire (MEQ), Depression Anxiety Stress Scales-42 (DASS-42), and General Health Questionnaire-28 (GHQ-28). Statistical analyses, including Spearman’s correlation and Kruskal-Wallis tests, evaluated the relationships between sleep quality, chronotype, and ED. The average age was 31.03 ± 8.06 years. Significant correlations were found: Poor sleep quality was linked to lower erectile function (r = −0.379, p < 0.001), while morning chronotype correlated with better erectile function (r = 0.424, p < 0.001). Regression analysis confirmed these as significant predictors of ED (R 2 = 0.200, p < 0.001). Sleep quality and chronotype are crucial factors in ED management, suggesting targeted interventions could be beneficial.

28 September 2024 in BMC Urology
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
RTRojda Tanrıverdi
Rojda Tanrıverdi
MBMert Başaranoğlu
Mert Başaranoğlu
BSBarış Saylam
Barış Saylam
EUErcüment Ulusoy
Ercüment Ulusoy
SESemra Erdoğan
Semra Erdoğan
Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy. Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR. The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker. The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.

1 June 2025 in Bladder Cancer
Verified
Journal Article
Open access
ANAli Nebioğlu
Ali Nebioğlu
MBMert Başaranoğlu
Mert Başaranoğlu
MBMurat Bozlu
Murat Bozlu
YKYasemin Yuyucu Karabulut
Yasemin Yuyucu Karabulut
Purpose: This study aimed to evaluate the impact of lymphovascular invasion (LVI) and histologic subtypes on prognosis following Bacillus Calmette-Guérin (BCG) therapy in high-grade non-muscle invasive bladder cancer (NMIBC). Methods: We retrospectively analyzed 245 patients who underwent transurethral resection of bladder tumor (TURBT) for high-grade Ta, T1, or carcinoma in situ (CIS) and received BCG therapy between January 2010 and December 2020. Effects of LVI and histologic subtypes on recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Results: At median follow-up of 48.5 months, LVI was detected in 25.7% of patients and histologic subtypes in 36.3%. During follow-up, disease recurrence occurred in 98 patients (40.0%) and progression in 45 patients (18.4%). In multivariate analysis, LVI (HR: 2.28, 95% CI: 1.68–3.10, p < 0.001) and histologic subtypes ≥1% (HR: 1.95, 95% CI: 1.45–2.62, p < 0.001) were independent risk factors for recurrence. Similarly, LVI (HR: 2.85, 95% CI: 1.98–4.11, p < 0.001) and histologic subtypes ≥1% (HR: 2.34, 95% CI: 1.67–3.28, p < 0.001) were independent risk factors for progression. Patients with concurrent LVI and histologic subtypes demonstrated highest risk of progression (HR: 4.15, 95% CI: 2.85–6.05, p < 0.001) with 5-year PFS rate of 45.2%. Conclusion: In high-grade NMIBC patients receiving BCG therapy, LVI and histologic subtypes are strong independent risk factors for disease recurrence and progression. Patients with both factors have highest risk and may require more aggressive treatment strategies including consideration of early radical cystectomy. These findings support the importance of detailed pathological assessment in treatment selection for BCG-treated NMIBC patients.

25 December 2024 in Üroonkoloji Bülteni
Verified
Journal Article
Closed access
ANAli Nebioğlu
Ali Nebioğlu
ÖIÖmer Işık
Ömer Işık
BSBarış Saylam
Barış Saylam

29 June 2025 in The New Journal of Urology
Verified
Journal Article
Open access
ATAhmet Turhan
Ahmet Turhan
MBMert Başaranoğlu
Mert Başaranoğlu
ANAli Nebioğlu
Ali Nebioğlu
EAErdem Akbay
Erdem Akbay
One of the long-term complications of urinary diversion, urolithiasis, is influenced by factors such as bacterial colonization, urinary stasis, mucus, and anatomical abnormalities. Stones are typically observed in the upper urinary tract, and they are rarely seen in the ileal conduit. Although endoscopic surgery can be used for the treatment of stones in the ileal conduit, it is predominantly treated with open surgery. We report a 28-year-old male patient with 282 urinary stones, the largest of which measures 8 cm, found in the ileal conduit. The case is evaluated in terms of treatment and surgical approaches. Keywords: ileal conduit, lithotripsy, urolithiasis, urinary diversion

1 January 2025 in Journal of Reconstructive Urology
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
MBMert Başaranoğlu
Mert Başaranoğlu
MTMesut Tek
Mesut Tek
EAErdem Akbay
Erdem Akbay
Objective: To evaluate the efficacy, safety, and clinical outcomes of retrograde intrarenal surgery in a large patient cohort and identify factors affecting treatment success across different demographic groups. Material and Methods: This retrospective study analyzed 3,781 patients who underwent retrograde intrarenal surgery between January 2013 and December 2023. Patient demographics, stone characteristics, operative parameters, and complications were evaluated. Stone-free rates, operative times, and complications were assessed according to stone location and size. The primary outcome was stone-free status evaluated by non-contrast computed tomography at 3 months postoperatively. Multivariate analysis was performed to identify predictors of treatment success. Results: The overall stonefree rate was 88.7%. Mean stone size was 13.9±5.6 mm, with mean operative time of 52 minutes. Stone distribution was: lower calyx (42.5%), renal pelvis (30.0%), upper calyx (15.2%), and middle calyx (12.3%). Total complication rate was 12.5%, with minor complications (ClavienDindo Grade I-II) occurring in 11.4%, moderate complications (Grade III) in 1.0%, and major complications (Grade IV) in 0.05% of cases. Multivariate analysis identified stone size >15mm (odds ratio [OR]: 0.68, p<0.001), lower calyx location (OR: 0.75, p=0.004), and multiple stones (OR: 0.82, p=0.042) as significant predictors of treatment success. Patient satisfaction averaged 8.4 out of 10, showing strong correlation with stone-free status (correlation coefficient: 0.85, p<0.001). Conclusion: Retrograde intrarenal surgery demonstrates high efficacy and safety in treating upper urinary tract stones, with favorable outcomes across different patient groups. Stone size, location, and multiplicity significantly influence treatment success, while complication rates remain low with standardized technique. These findings can aid in optimizing patient selection and improving preoperative counseling.